Executive Profile: Luciano Rossetti, chief cartographer for Merck Serono's R&D roadmap
This article was originally published in Scrip
Executive Summary
Dr Luciano Rossetti was appointed global head of R&D at Merck Serono in July 2014, moving over from Merck & Co, where he had been senior vice-president of late stage development. Before joining Merck & Co [Merck Sharp & Dohme/MSD] as franchise head for diabetes and obesity in 2006, he had had a long and distinguished career in academia, focused on diabetes research in particular. A native of Naples, he moved to the US after completing medical training in Italy. He talked to Scrip's Eleanor Malone about leadership, pipeline pruning, switching careers and more.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.